fluorescein Search Results


95
Dojindo Labs fluorescein labeling kit nh2
Fluorescein Labeling Kit Nh2, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescein labeling kit nh2/product/Dojindo Labs
Average 95 stars, based on 1 article reviews
fluorescein labeling kit nh2 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

93
R&D Systems mouse
Mouse, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse/product/R&D Systems
Average 93 stars, based on 1 article reviews
mouse - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

92
Rockland Immunochemicals rabbit anti collagen vi
Rabbit Anti Collagen Vi, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti collagen vi/product/Rockland Immunochemicals
Average 92 stars, based on 1 article reviews
rabbit anti collagen vi - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

93
Rockland Immunochemicals cy3 conjugated donkey anti rabbit igg
Cy3 Conjugated Donkey Anti Rabbit Igg, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cy3 conjugated donkey anti rabbit igg/product/Rockland Immunochemicals
Average 93 stars, based on 1 article reviews
cy3 conjugated donkey anti rabbit igg - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

98
Jackson Immuno fitc conjugated goat anti mouse secondary antibody
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Fitc Conjugated Goat Anti Mouse Secondary Antibody, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc conjugated goat anti mouse secondary antibody/product/Jackson Immuno
Average 98 stars, based on 1 article reviews
fitc conjugated goat anti mouse secondary antibody - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier

93
Jackson Immuno fitc anti mouse secondary antibody
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Fitc Anti Mouse Secondary Antibody, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc anti mouse secondary antibody/product/Jackson Immuno
Average 93 stars, based on 1 article reviews
fitc anti mouse secondary antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
R&D Systems human vegfr2 kdr flk 1 fluorescein conjugated antibody
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Human Vegfr2 Kdr Flk 1 Fluorescein Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegfr2 kdr flk 1 fluorescein conjugated antibody/product/R&D Systems
Average 93 stars, based on 1 article reviews
human vegfr2 kdr flk 1 fluorescein conjugated antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

96
Jackson Immuno anti gt fitc
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Anti Gt Fitc, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti gt fitc/product/Jackson Immuno
Average 96 stars, based on 1 article reviews
anti gt fitc - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

93
Jackson Immuno fluorescein fitc affinipuretm
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Fluorescein Fitc Affinipuretm, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fluorescein fitc affinipuretm/product/Jackson Immuno
Average 93 stars, based on 1 article reviews
fluorescein fitc affinipuretm - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

95
Rockland Immunochemicals polyclonal fitc conjugated anti gfp
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Polyclonal Fitc Conjugated Anti Gfp, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal fitc conjugated anti gfp/product/Rockland Immunochemicals
Average 95 stars, based on 1 article reviews
polyclonal fitc conjugated anti gfp - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

93
Rockland Immunochemicals secondary anti mouse fitc antibody
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Secondary Anti Mouse Fitc Antibody, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/secondary anti mouse fitc antibody/product/Rockland Immunochemicals
Average 93 stars, based on 1 article reviews
secondary anti mouse fitc antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

93
Rockland Immunochemicals polyclonal anti collagen type 1
p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with <t>FITC</t> (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant
Polyclonal Anti Collagen Type 1, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal anti collagen type 1/product/Rockland Immunochemicals
Average 93 stars, based on 1 article reviews
polyclonal anti collagen type 1 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with FITC (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant

Journal: Cellular and Molecular Neurobiology

Article Title: CREB2 Functions as a Central Mediator of Oxidative Neuronal Death Triggered by Microglial Glutamate Release Under Neuroinflammatory Conditions

doi: 10.1007/s10571-026-01695-w

Figure Lengend Snippet: p53 inhibition suppresses glutamate-induced CREB2 activation and downstream cytotoxic signaling. A HT22 cells were pretreated with 10 µM PFTα (a p53 inhibitor) for 1 h, followed by 5 mM glutamate (Glu) exposure for an additional 24 h. Protein levels of CREB2 and GADD45α were assessed by Western blotting and quantified (left panels). Cell viability was measured using the MTT assay (right panel). B Immunofluorescence staining of CREB2 was performed following the same treatment as in ( A ). Representative images show nuclei stained with Hoechst and CREB2 with FITC (scale bar = 50 μm). C Cells were transfected with p53 siRNA (sip53) for 24 h, followed by 5 mM glutamate treatment for an additional 24 h. Western blotting for CREB2 and p53 and their quantification (left panels) are shown. Cell viability was determined using the MTT assay (right panel). D Cells were transfected with CREB2 siRNA (siCREB2) for 24 h prior to glutamate treatment (5 mM, 24 h). Western blotting was performed to assess expression of phosphorylated p53 (Ser15), CREB2, and GADD45α (left panels). Quantification is shown in the left panel. Cell viability was assessed by MTT assay (right panel). E Cells were transfected with GADD45α siRNA (siGADD45α) for 24 h, followed by glutamate treatment (5 mM, 24 h). Protein levels of CREB2 and GADD45α were analyzed by Western blotting and quantified. Data are presented as mean ± SD ( n = 3). GAPDH served as a loading control. Statistical significance was determined using the following tests: One-way ANOVA with Bonferroni’s post hoc test for MTT in ( A ) [F(3, 8) = 333, p < 0.0001], ( C ) [F(3, 8) = 282, p < 0.0001], and ( D ) [F(3, 8) = 269.6, p < 0.0001]; and Two-way ANOVA with Bonferroni’s post hoc test for WB quantification in ( A ) [F(3, 16) = 437.4, p < 0.0001], ( C ) [F(3, 16) = 12.85, p = 0.0002], ( D ) [F(3, 24) = 83.83, p < 0.0001], and ( E ) [F(3, 16) = 1054, p < 0.0001]. Asterisks indicate statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant

Article Snippet: After three washes, cells were incubated with FITC-conjugated goat anti-mouse secondary antibody (1:200; Jackson ImmunoResearch, cat. no. 115-095-003) for 1 h. Nuclei were counterstained with 5 μM Hoechst 33,342 (stock solution diluted immediately prior to use; Thermo Fisher Scientific, Cat. No. H1399) for 5 min at room temperature.

Techniques: Inhibition, Activation Assay, Western Blot, MTT Assay, Immunofluorescence, Staining, Transfection, Expressing, Control